Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
| Bimzelx | bimekizumab | Psoriatic arthritis | Active | |||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
| TBC | momelotinib | Myelofibrosis | Pending | |||
| Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
| TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| Velsipity | etrasimod | Ulcerative colitis | Active |
Last Updated : May 10, 2024